ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
8.21
+0.52 (6.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
ORIC Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ORIC stock have an average target of 18.75, with a low estimate of 14 and a high estimate of 25. The average target predicts an increase of 128.38% from the current stock price of 8.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 4, 2024.
Analyst Ratings
The average analyst rating for ORIC stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +155.79% | Nov 4, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +107.06% | Oct 31, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +155.79% | Sep 18, 2024 |
| Wedbush | Wedbush | Buy Reiterates $20 | Buy | Reiterates | $20 | +143.61% | Sep 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.87
from -1.96
EPS Next Year
-2.09
from -1.87
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 40.1M | |||
| Avg | n/a | n/a | 12.0M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.82 | -1.71 | -1.61 | |||
| Avg | -1.87 | -2.09 | -2.05 | |||
| Low | -1.82 | -2.32 | -2.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.